Gilead Sciences, Inc. $GILD Stock Sold by Profund Advisors LLC

Profund Advisors LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 107,861 shares of the biopharmaceutical company’s stock after selling 3,007 shares during the period. Profund Advisors LLC’s holdings in Gilead Sciences were worth $16,077,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Gilead Sciences during the second quarter worth $15,393,785,000. State Street Corp boosted its holdings in shares of Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after buying an additional 1,357,967 shares during the last quarter. Amundi increased its holdings in shares of Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after acquiring an additional 1,018,976 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Gilead Sciences during the second quarter worth approximately $1,316,606,000. Finally, Deutsche Bank AG acquired a new stake in Gilead Sciences during the second quarter worth approximately $918,387,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel O’Day sold 15,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $147.90, for a total value of $2,218,500.00. Following the completion of the sale, the chief executive officer directly owned 566,683 shares of the company’s stock, valued at approximately $83,812,415.70. This represents a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent research reports. Citigroup lifted their target price on shares of Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a research report on Friday. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday. TD Cowen increased their price target on shares of Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a report on Friday. Scotiabank lifted their price objective on Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a report on Friday. Finally, UBS Group restated a “buy” rating and issued a $195.00 price objective on shares of Gilead Sciences in a report on Friday. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $169.19.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Price Performance

Shares of GILD stock opened at $170.68 on Friday. The company has a market cap of $211.63 billion, a P/E ratio of -54.01 and a beta of 0.31. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock’s 50-day moving average is $150.87 and its 200 day moving average is $139.79. Gilead Sciences, Inc. has a 1-year low of $114.02 and a 1-year high of $175.65.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.47 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is -103.80%.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.